Thrombotic Effects of Yellowstripe Scad

The Thrombotic Effects of Yellowstripe Scad (YSS) Compared to Salmon Among Healthy Overweight Subjects: A Randomized Cross Over Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03251014

Enrollment

Registered

2017-08-16

Start date

2016-10-31

Completion date

2017-05-09

Last updated

2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombosis

Keywords

Thrombosis, Yellowstripe scad, Salmon, Healthy overweight subjects, Randomized crossover trial

Brief summary

The study aimed to determine the thrombotic effects of YSS compared with salmon among healthy overweight subjects. It hypothesized that YSS may result significant, favorable thrombotic effects and the effects may be similar with salmon.

Detailed description

The project was a randomized, two-period, crossover trial with 8-week treatment periods and 8-week washout period. A total of 50 healthy overweight adults were recruited among staff and students in UPM. All the subjects were randomized into two groups. Each group was served with either cooked YSS (\ 265 g/ day) or salmon (\ 246 g/day) thrice per week. Blood and urine samples were collected for laboratory assessment.

Interventions

OTHERYSS

Intervention providing steamed whole YSS (\ 265 g/day, 3 days/week) for eight weeks

OTHERSalmon

Intervention providing steamed salmon fillet (\ 246 g/day, 3 days/week) for eight weeks

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Malaysian * Overweight participants (BMI 23-27.4 kg/m2)

Exclusion criteria

* Regular use of fish oil supplements during the last one month * Regular consumption of fish twice or more per week * Vegetarian who excluded all meat, fish, and poultry from their diet * Diagnosed with cardiovascular disease, haemostasis disorder, inflammatory disease, diabetes mellitus, hypertension, or other significant medical history that may prohibits the participation * Receiving warfarin or aspirin treatment, or medication to lower serum lipids, blood pressure, and inflammation * Women who are menopause, pregnant or lactating

Design outcomes

Primary

Measure	Time frame	Description
Changes in hemostatic status assessed by immunoassay method	8 weeks	Hemostatic markers including vWF-A2 and CD62b (p-selectin) in pg/mL are evaluated.

Secondary

Measure	Time frame	Description
Changes in lipid and glucose profiles analysed by medical diagnostic laboratory	8 weeks	Total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, and fasting blood glucose in mmol/L are evaluated.
Changes in liver enzymes analysed by medical diagnostic laboratory	8 weeks	Serum levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline Phosphatase (ALP) and gamma glutamyl transferase (GGT) in IU/L are determined.
Changes in renal function analysed by medical diagnostic laboratory	8 weeks	Serum levels of creatinine, urea, and electrolytes (sodium, potassium, and chloride) in mmol/L are determined.
Changes in body mass index (BMI)	8 weeks	Weight and height are combined to report BMI in kg/m\^2
Changes in blood pressure	8 weeks	Seated systolic and diastolic blood pressures are taken in mmHg.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026